Home Contact Us Site Map
Search for:
Classes & Programs Services
Health Info Find a Job Find a Physician
Mercy Health Center-Fort Scott
Mercy Hospital-Independence
Mercy Physician Group
Mercy Foundations
Health for Life-Fitness Centers
Web Nursery
Women's Services
Visitor Information
Volunteer Opportunities
Privacy Statement
 
Home > Health Information > E-Newsletters > Heart Health 

Simpler Bypass Surgery Makes a Difference 

Minimally invasive technique more effective than other procedures, study finds

The increasing availability of a surgical technique that uses a small incision for bypass surgery is making a difference.

The technique, minimally invasive bypass surgery, now is preferable for many patients who otherwise would be treated with the artery-opening procedure called angioplasty, says a report in a recent issue of the New England Journal of Medicine. Angioplasty is a procedure in which thin balloons and other devices are threaded into a coronary artery and inflated to remove plaque that has blocked blood flow.

With the minimally invasive technique, the surgeon can do a bypass procedure through an incision as small as 4 inches, rather than sawing open the breastbone, as is done in conventional bypass surgery. Minimally invasive surgery can be done on the beating heart; conventional surgery requires the heart be stopped and the patient put on a heart-lung machine.

In the latest study, cardiologists at the University of Leipzig Heart Center in Germany compared the outcome of the minimally invasive technique to angioplasty followed by the implantation of a stent, a tube designed to keep the blood vessel open. Included in the study were 220 patients with blockage of a major heart vessel, the left anterior descending coronary artery.

This is "a very important coronary artery, and one that is at high risk for restenosis," says lead author Dr. Gerhard Schuler, a professor of medicine at Leipzig. Restenosis is a potentially life-threatening closing of the artery after its blood flow has been restored by angioplasty or a bypass.

The study was done because balloon angioplasty followed by stenting has become the standard procedure for the condition, but no studies have compared stenting with minimally invasive bypass, Schuler says. In the study, half the patients had stenting, the other half had minimally invasive bypass surgery.

Overall, the results favored bypass surgery, Schuler says. The incidence of complications immediately after the procedure was higher for the surgery patients, but after six months only 21 percent of the bypass patients had angina—chest pain caused by artery blockage—compared with 38 percent of the angioplasty-stent patients. Restenosis occurred in 29 percent of the stent patients, compared with 5 percent of the bypass patients. And 31 percent of the stent patients had a major cardiac event such as a heart attack, compared to 16 percent of the bypass patients.

Those results indicate that bypass surgery is a preferable treatment, but only if it is done with the minimally invasive method, in which "surgical trauma is much less severe and the hospital stay is shorter," Schuler says.

Other medical conditions influence the decision, he adds: "For patients at high risk of stenosis, such as those with diabetes, we feel that they should undergo bypass surgery, conventional or minimally invasive."

Also, the arrival of a new generation of stents that are coated with drugs designed to prevent the artery from closing might make a difference, says an accompanying editorial by Dr. Thomas E. MacGillivray and Dr. Gus J. Vlahakas, both of Massachusetts General Hospital.

"Recent studies using drug-coated stents suggest that these devices reduce...recurrent stenosis, although long-term data are not yet available," they write.

Always consult your physician for more information.

September 2002

Minimally Invasive Technique Shown More Effective Than Other Procedures, Study Finds

The Tale of Two Heart Drugs

Online Resources

Find a Sisters of Mercy Health System Physician


In Other News About Your Heart:

The Tale of Two Heart Drugs

A study in a recent issue of The Lancet clarifies the differences between two similar drugs given to people who have angioplasty to treat narrowed coronary arteries.

The drugs, tirofiban and abciximab, are used to reduce the clumping together of platelets in the blood, something that can cause complications during procedures to open narrowed arteries.

This study looked at outcomes for 4,809 people six months after they had coronary-artery angioplasty with stent placement. They found that 14.8 percent of the people who took tirofiban died, had a heart attack or had repeat surgery within those six months, compared to 14.3 percent of the people who took abciximab.

The study concludes that both drugs are similar in terms of preventing these long-term events. An earlier study by the same researchers showed that abciximab was significantly better than tirofiban at preventing death, heart attacks, and repeat surgery within 30 days after people had angioplasty for narrowed coronary arteries.

"As studied, abciximab was more protective against a heart attack occurring during, or immediately following angioplasty. Yet the two drugs were associated with similarly low rates of death and renarrowing of the heart's arteries at six months. Our conclusion is that, while the more expensive drug (abciximab) is better 'up front', it provides little long-term advantage compared with tirofiban," says the study's lead author, Dr. David Moliterno of the Cleveland Clinic Foundation.

Always consult your physician for more information.


Online Resources       

American Heart Association

The Lancet

National Heart, Lung, and Blood Institute (NHLBI)

New England Journal of Medicine

A member of the
Sisters of Mercy Health System